Biomarkers for the diagnosis and management of cardiovascular-kidney-metabolic syndrome: recent advances and prospects for clinical application
- 1Changzhou Medical Center, Nanjing Medical University
- 2The First People’s Hospital of Changzhou
Abstract
Cardiovascular-kidney-metabolic (CKM) syndrome describes a multidirectional network linking dysfunctional adiposity, metabolic risk factors, kidney disease and cardiovascular injury. Its early stages are often clinically silent, while obesity, impaired kidney function, multimorbidity and recent exercise can alter the concentrations and interpretation of commonly used biomarkers. This narrative review, informed by a structured literature search, evaluates biomarkers across screening, risk stratification, treatment monitoring and precision phenotyping, while distinguishing CKM-specific evidence from evidence extrapolated from chronic kidney disease, diabetes, obesity and heart-failure populations. Established clinical biomarkers, including estimated glomerular filtration rate, urine albumin-to-creatinine ratio, B-type natriuretic peptide/N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin, remain the foundation of clinical assessment. Emerging evidence spans directly measured markers of inflammation, oxidative stress and organ injury; indices derived from routine clinical variables; and metabolomic, lipidomic and other multi-omics platforms. Most of these measures provide biological or prognostic information but remain investigational because prospective external validation, analytical standardisation, actionable thresholds, incremental net benefit and biomarker-guided intervention evidence are limited. Lifestyle and exercise act both as upstream modifiers of CKM biology and as interpretive factors for several biomarkers. A clinically useful CKM biomarker framework should therefore integrate evidence maturity, population relevance, cross-organ specificity, serial trajectories, cost and equity. Emerging biomarkers should complement rather than replace established assessment until prospective studies demonstrate that their use changes treatment decisions and improves patient outcomes.
Related
- The Multifaceted Roles of Biomarkers in Metabolic Disorders: From Diagnosis and Monitoring to Prediction, Management, and Treatment
- Biomarkers and Risk Prediction in Cardiovascular–Kidney–Metabolic Syndrome: A Comprehensive Review
- Reply to Crespo, J.; Iruzubieta, P. Comment on "Orozco-Beltrán et al. Evaluation, Management and Therapeutic Approach of Cardiovascular-Kidney-Metabolic Syndrome: A Multidisciplinary Delphi Expert Consensus. J. Clin. Med. 2025, 14, 8930".
- 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
- Community-Level Wastewater Surveillance of Nicotine Biomarkers Tracks Cardiovascular Disease Burden and Myocardial Infarction
BibTeX
@article{hu2026biomarkers,
title = {{Biomarkers for the diagnosis and management of cardiovascular-kidney-metabolic syndrome: recent advances and prospects for clinical application}},
author = {Liuqi Hu and Min Yang},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1989794},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1989794/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Biomarkers for the diagnosis and management of cardiovascular-kidney-metabolic syndrome: recent advances and prospects for clinical application
AU - Liuqi Hu
AU - Min Yang
PY - 2026
DA - 2026/10/21
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1989794
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1989794/full
AB - Cardiovascular-kidney-metabolic (CKM) syndrome describes a multidirectional network linking dysfunctional adiposity, metabolic risk factors, kidney disease and cardiovascular injury. Its early stages are often clinically silent, while obesity, impaired kidney function, multimorbidity and recent exercise can alter the concentrations and interpretation of commonly used biomarkers. This narrative review, informed by a structured literature search, evaluates biomarkers across screening, risk stratification, treatment monitoring and precision phenotyping, while distinguishing CKM-specific evidence from evidence extrapolated from chronic kidney disease, diabetes, obesity and heart-failure populations. Established clinical biomarkers, including estimated glomerular filtration rate, urine albumin-to-creatinine ratio, B-type natriuretic peptide/N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin, remain the foundation of clinical assessment. Emerging evidence spans directly measured markers of inflammation, oxidative stress and organ injury; indices derived from routine clinical variables; and metabolomic, lipidomic and other multi-omics platforms. Most of these measures provide biological or prognostic information but remain investigational because prospective external validation, analytical standardisation, actionable thresholds, incremental net benefit and biomarker-guided intervention evidence are limited. Lifestyle and exercise act both as upstream modifiers of CKM biology and as interpretive factors for several biomarkers. A clinically useful CKM biomarker framework should therefore integrate evidence maturity, population relevance, cross-organ specificity, serial trajectories, cost and equity. Emerging biomarkers should complement rather than replace established assessment until prospective studies demonstrate that their use changes treatment decisions and improves patient outcomes.
SN - 1664-2392
ER -